Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RAPID-SEP-AST

Financiado

Cerrado

Rapid diagnostic for bacterial SEPSIS and AMR urgently needed for ICU patients i...

Rapid diagnostic for bacterial SEPSIS and AMR urgently needed for ICU patients in COVID 19 like epidemics SEPSIS is a life-threatening reaction to infection with 48.9 million cases and 11 million deaths worldwide, 700.000 of those in the EU yearly. In epidemic-like situations such as COVID-19, SEPSIS is prevalent in >60% of the admitt... ver más

31/07/2022

RESISTELL AG

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

RESISTELL AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-07-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

RESISTELL AG

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SMARTDIAGNOS Next generation sepsis diagnosis 5M€ Cerrado

KlotoDx KlotoDx A quick and cost effective near patient tool to iden... 71K€ Cerrado

QuickMIC QuickMIC an ultra rapid diagnostic system for Antibiotic... 71K€ Cerrado

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

FIT-SEP Fully integrated technology for predictive diagnosis of seps... 197K€ Cerrado

RAPP-ID Development of RApid Point of Care test Platforms for Infect... 16M€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2020-07-15
Fecha Fin: 2022-07-31

Líder del proyecto

RESISTELL AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto SEPSIS is a life-threatening reaction to infection with 48.9 million cases and 11 million deaths worldwide, 700.000 of those in the EU yearly. In epidemic-like situations such as COVID-19, SEPSIS is prevalent in >60% of the admitted patients and all non-survivors had SEPSIS. SEPSIS patients require immediate antibiotic therapy to prevent disease progression and reduce mortality. Therefore, clinicians administer empirically broad-spectrum antibiotics, which save lives but also lead to inappropriate treatments in up to 40% of cases. To identify the best antibiotic and dosage for each patient, clinicians in Acute Care and ICUs need to run diagnostics to identify both the pathogen causing the infection but test several antibiotics to find the specifically treating the infection. Antibiotic susceptibility testing takes too long to be useful in SEPSIS cases. Resistell, a Deep-Tech SME, has a breakthrough AST technology delivers AST diagnostic results in less than 2h instead of the current 24-48h. Clinicians around the world using RAPID-SEP-AST will for the first time select personalised antibiotic therapies to SEPSIS patients in the same day, increasing the success rate of treatment and reducing hospitalisation time and costs. This EIC project will accelerate RAPID-SEP-AST industrialisation, finalise CE-IVD approval and support market-critical proof of efficiency in a multicentre performance evaluation study at KOLs. RAPID-SEP-AST will allow rapid Resistell scale-up first in Europe using its strong network of EU distributors and then globally through leading global distributors. Resistell’s is a Women-Led Company (Danuta Cichocka CEO) with a strong cross-functional team of engineers, microbiologists, data scientists and serial entrepreneurs, supported by experienced Board of Directors and Scientific Advisors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores